Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations

DOI: 10.2459/jcm.0b013e3283232a45
Journal of Cardiovascular Medicine, 2009, 10, 354-62.

#	Paper	IF	Citations
61	Transforming growth factor-{beta}: a biomarker in Marfan syndrome?. *Circulation*, **2009**, 120, 464-6	16.7	7
60	Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation. *Nature Reviews Cardiology*, **2009**, 6, 543-52	14.8	109
59	Drug-based therapies for vascular disease in Marfan syndrome: from mouse models to human patients. *Mount Sinai Journal of Medicine*, **2010**, 77, 366-73		9
58	Spontaneous arterial dissection: phenotype and molecular pathogenesis. *Cellular and Molecular Life Sciences*, **2010**, 67, 1799-815	10.3	32
57	Impact of Mendelian inheritance in cardiovascular disease. *Annals of the New York Academy of Sciences*, **2010**, 1214, 122-37	6.5	10
56	Adults with genetic syndromes. *International Journal on Disability and Human Development*, **2010**, 9,		
55	Does medical therapy for thoracic aortic aneurysms really work? Are beta-blockers truly indicated? CON. *Cardiology Clinics*, **2010**, 28, 261-9	2.5	13
54	Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. *Archives of Cardiovascular Diseases*, **2010**, 103, 317-25	2.7	59
53	Marfan Syndrome An Echocardiographer Perspective. *Journal of Medical Ultrasound*, **2011**, 19, 1-6	0.8	2
52	Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine. *British Journal of Clinical Pharmacology*, **2011**, 72, 6-17	3.8	6
51	The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications. *Pharmacology & Therapeutics*, **2011**, 131, 50-60	13.9	40
50	Genetic dissection of marfan syndrome and related connective tissue disorders: an update 2012. *Molecular Syndromology*, **2012**, 3, 47-58	1.5	29
49	Marfan syndrome: from gene to therapy. *Current Opinion in Pediatrics*, **2012**, 24, 498-504	3.2	44
48	Aortic event rate in the Marfan population: a cohort study. *Circulation*, **2012**, 125, 226-32	16.7	117
47	The Ghent Marfan Trial--a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with blockers. *International Journal of Cardiology*, **2012**, 157, 354-8	3.2	51
46	An evidence-based hypothesis for beneficial effects of telmisartan on Marfan syndrome. *International Journal of Cardiology*, **2012**, 158, 101-2	3.2	4
45	Surgical management of patients with Marfan syndrome: evolution throughout the years. *Archives of Cardiovascular Diseases*, **2012**, 105, 84-90	2.7	4

44	Extra-aortic identifiers to guide genetic testing in familial thoracic aortic aneurysms and dissections syndromes: it is all about the company one keeps. *Journal of the American College of Cardiology*, **2012**, 60, 404-7	15.1	3
43	Medical therapy of thoracic aortic aneurysms. *Trends in Cardiovascular Medicine*, **2012**, 22, 180-4	6.9	12
42	Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome - a randomised, double-blind, crossover trial. *European Journal of Clinical Investigation*, **2012**, 42, 891-9	4.6	31
41	The 8th international research symposium on the Marfan syndrome and related conditions. *American Journal of Medical Genetics, Part A*, **2012**, 158A, 42-9	2.5	20
40	Aortic dilatation and aortopathy in congenital heart diseases. *Journal of Cardiology*, **2013**, 61, 16-21	3	28
39	Genetic biomarkers in aortopathy. *Biomarkers in Medicine*, **2013**, 7, 547-63	2.3	6
38	Medical treatment for thoracic aortic aneurysm - much more work to be done. *Progress in Cardiovascular Diseases*, **2013**, 56, 103-8	8.5	8
37	High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 378-86	11.5	114
36	Educational paper. Connective tissue disorders with vascular involvement: from gene to therapy. *European Journal of Pediatrics*, **2013**, 172, 997-1005	4.1	22
35	Proteomics in aortic aneurysm--what have we learnt so far?. *Proteomics - Clinical Applications*, **2013**, 7, 504-15	3.1	5
34	A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome. *Cardiology in the Young*, **2013**, 23, 568-81	1	12
33	Medical treatment of aortic aneurysms in Marfan syndrome and other heritable conditions. *Current Cardiology Reviews*, **2014**, 10, 161-71	2.4	27
32	Atenolol versus losartan in children and young adults with Marfan's syndrome. *New England Journal of Medicine*, **2014**, 371, 2061-71	59.2	347
31	Loeys-Dietz syndrome. *Advances in Experimental Medicine and Biology*, **2014**, 802, 95-105	3.6	65
30	Clinical, diagnostic, and therapeutic aspects of the Marfan syndrome. *Advances in Experimental Medicine and Biology*, **2014**, 802, 77-94	3.6	15
29	Beta-blockers for preventing aortic dissection in Marfan's syndrome. *The Cochrane Library*, **2014**,	5.2	2
28	Losartan therapy for cardiac disease in paediatricMarfan syndrome. *Journal of Paediatrics and Child Health*, **2015**, 51, 927-31	1.3	1
27	Marfan Syndrome. **2015**, 157-212		

26	Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration. *American Heart Journal*, **2015**, 169, 605-12	4.9	35
25	Molecular pathogenesis of Marfan syndrome. *International Journal of Cardiology*, **2015**, 187, 585-91	3.2	43
24	A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes. *International Journal of Cardiology*, **2015**, 179, 470-5	3.2	31
23	Angiotensin receptor blockers: a panacea for Marfan syndrome and related disorders?. *Drug Discovery Today*, **2015**, 20, 262-6	8.8	21
22	The effect of losartan on progressive aortic dilatation in patients with Marfan's syndrome: a meta-analysis of prospective randomized clinical trials. *International Journal of Cardiology*, **2016**, 217, 190-4	3.2	27
21	Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications. *Canadian Journal of Cardiology*, **2016**, 32, 66-77	3.8	26
20	Histopathology of aortic complications in bicuspid aortic valve versus Marfan syndrome: relevance for therapy?. *Heart and Vessels*, **2016**, 31, 795-806	2.1	27
19	Editor's Choice - Management of Descending Thoracic Aorta Diseases: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). *European Journal of Vascular and Endovascular Surgery*, **2017**, 53, 4-52	2.3	487
18	'Precision and personalized medicine,' a dream that comes true?. *Journal of Cardiovascular Medicine*, **2017**, 18 Suppl 1, e1-e6	1.9	5
17	Beta-blockers for preventing aortic dissection in Marfan syndrome. *The Cochrane Library*, **2017**, 11, CD011103	5.1	15
16	Pathogenesis of aortic wall complications in Marfan syndrome. *Cardiovascular Pathology*, **2018**, 33, 62-69	3.8	21
15	Current Status of Medical Therapy of Thoracic Aortic Aneurysm and Dissection. **2018**, 235-249		
14	Precise Therapy for Thoracic Aortic Aneurysm in Marfan Syndrome: A Puzzle Nearing Its Solution. *Progress in Cardiovascular Diseases*, **2018**, 61, 328-335	8.5	13
13	Update on Clinical Trials of Losartan With and Without Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review. *JAMA Cardiology*, **2019**, 4, 702-707	16.2	26
12	Management of a giant aortic root aneurysm in a young patient with Marfan syndrome: a case report. *Journal of Cardiothoracic Surgery*, **2020**, 15, 264	1.6	
11	Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial. *European Heart Journal*, **2020**, 41, 4181-4187	9.5	27
10	An Overview of Investigational and Experimental Drug Treatment Strategies for Marfan Syndrome. *Journal of Experimental Pharmacology*, **2021**, 13, 755-779	3	1
9	The Future of Dupuytren Research and Treatment. **2012**, 455-470		1

8	Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. *Journal of Clinical Investigation*, **2014**, 124, 1329-39	15.9	86
7	A healthy tension in translational research. *Journal of Clinical Investigation*, **2014**, 124, 1425-9	15.9	7
6	Association between Oro-Facial Defects and Systemic Alterations in Children Affected by Marfan Syndrome. *Journal of Clinical and Diagnostic Research JCDR*, **2013**, 7, 700-3	0	7
5	The Clinical Genetics of Thoracic Aortic Disease. **2014**, 3-15		
4	Loeys-Dietz Syndrome. *Advances in Experimental Medicine and Biology*, **2021**, 1348, 251-264	3.6	1
3	Aortic Wall Inflammation in the Pathogenesis, Diagnosis and Treatment of Aortic Aneurysms.. *Inflammation*, **2022**, 1	5.1	0
2	NADPH Oxidases in Aortic Aneurysms. **2022**, 11, 1830		0
1	Angiotensin receptor blockers and blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. **2022**, 400, 822-831		1